Genentech was able to demonstrate in mouse models that the new bispecific antibody was able to reach therapeutic levels in the brain. Genentech's method of disguising and transporting the therapeutic antibody by attaching it to a receptor-mediated transcytosis activator has been referred to as the "Trojan Horse" method.
Genentech was able to confirm in animal models that the new bispecific antibody attained therapeutic levels within the brain. Genentech's technique for concealing and transporting the therapeutic antibody by coupling it to a receptor-mediated transcytosis activator is referred to as the "Trojan Horse" method.